High-Mass MALDI Mass Spectrometry for Therapeutic Protein Aggregation Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for analyzing therapeutic protein aggregation, such as antibodies, are limited by the inability to quantify aggregates accurately in high-mass ranges and require correction factors specific to instrument setups, making them impractical for routine analysis.
Innovation Solution
A method using High-Mass MALDI ToF mass spectrometry with crosslinking chemistry to stabilize aggregates, allowing direct quantification of therapeutic protein aggregates without digestion or fragmentation, using a calibration curve to determine the amount of aggregation based on peak surface areas.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional ESI mass spectrometry is used to analyze antibody aggregates, then different species of aggregates can be distinguished, but quantitative analysis of aggregation amount is not possible
Solution Approach 1:
The patent introduces an affinity tag (such as a polyhistidine tag or FLAG tag) as an intermediary element that binds specifically to the therapeutic protein and its aggregates. This tag serves as a universal marker that enables detection and quantification of aggregates across different instrument setups without requiring instrument-specific correction factors, thereby achieving both accurate quantification and routine analysis capability
Solution Approach 2:
The patent changes the detection parameter by using affinity-tagged proteins instead of native proteins. This parameter change allows the use of affinity-based detection methods (such as affinity chromatography or affinity-based mass spectrometry) that provide quantitative data on aggregation levels, transforming the analysis from qualitative species distinction to quantitative aggregation measurement
2Measurement precision
If MALDI mass spectrometry is used to detect intact protein complexes in high-mass range, then non-covalent interactions can be preserved, but detection sensitivity is reduced or inexisting above 200 kDa
Solution Approach 1:
The patent segments the detection approach by separating the protein of interest from the complex high-mass aggregate structure. By using affinity tags that can be detected independently, the method enables sensitive detection of aggregates in the high-mass range without requiring direct detection of the entire aggregate complex, thus overcoming the sensitivity limitations of conventional MALDI mass spectrometry
Solution Approach 2:
The affinity tag acts as an intermediary that bridges the gap between the high-mass aggregate complex and the detection system. The tag provides a detectable signal that is proportional to the amount of aggregate present, enabling sensitive quantification of high-mass complexes that would otherwise be undetectable by conventional MALDI mass spectrometry
3Stability of the object's composition
If crosslinking reagents are used to stabilize aggregates for MALDI analysis, then intact aggregates can be detected, but the laser ionization disrupts non-covalent interactions
Solution Approach 1:
The patent applies crosslinking reagents as a preliminary action before MALDI analysis to stabilize the aggregate structure. This pre-stabilization ensures that the aggregates maintain their integrity during the subsequent laser ionization process, allowing detection of the crosslinked aggregates while minimizing disruption of the original non-covalent interactions
Solution Approach 2:
The patent converts the potentially harmful effect of laser-induced disruption into a beneficial outcome by using crosslinking reagents. The crosslinks act as a protective framework that prevents complete aggregate disintegration during laser ionization, allowing the detection of aggregate structures that would otherwise be completely disrupted, thus transforming a harmful effect into a useful stabilization mechanism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate and sensitive quantification of therapeutic protein aggregates, including low amounts, in both purified and heterogeneous samples, with high repeatability and applicability to various applications like drug development and quality control, without needing instrument-specific correction factors.
Implementation Method 1
contacting a mixture of monomeric and non-covalently aggregated therapeutic proteins with a crosslinking reagent to form covalently stabilized therapeutic protein aggregates
Implementation Method 2
analyzing the intact ions formed by High-Mass MALDI ToF mass spectrometry
Implementation Method 3
analyzing the intact ions formed by High-Mass MALDI ToF mass spectrometry
Data Source
AI summary
The invention relates to a method of using high-mass matrix assisted laser desorption-ionization (MALDI) mass spectrometry for the quantitative analysis of the amount of aggregation (dimers, trimers or multimers) of antibodies or other therapeutic proteins in purified pharmaceutical samples or complex biological matrices, as well as to the use of this method for characterization of antibodies, drug development and quality control of therapeutic proteins, including automated high throughput applications.